Swedish Orphan Biovitrum AB

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000872095
SEK
395.80
379.03 (2260.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Swedish Orphan Biovitrum AB
Camurus AB
BioArctic AB
Swedencare AB
Calliditas Therapeutics AB
Egetis Therapeutics AB
Hansa Biopharma AB
Vicore Pharma Holding AB
Xspray Pharma AB
Infant Bacterial Therapeutics AB
FluoGuide A/S

Why is Swedish Orphan Biovitrum AB ?

1
Healthy long term growth as Net Sales has grown by an annual rate of 12.34%
2
With a growth in Net Profit of 183.93%, the company declared Very Positive results in Jun 25
  • The company has declared positive results for the last 2 consecutive quarters
  • PRE-TAX PROFIT(Q) At SEK 1,031 MM has Grown at 238.03%
  • NET PROFIT(Q) At SEK 825.24 MM has Grown at 232.17%
  • DEBT-EQUITY RATIO (HY) Lowest at 30.09 %
3
With ROE of 11.90%, it has a attractive valuation with a 2.75 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 19.72%, its profits have risen by 102.5% ; the PEG ratio of the company is 0.2
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
5
Consistent Returns over the last 3 years
  • Along with generating 19.72% returns in the last 1 year, the stock has outperformed OMX Stockholm 30 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Swedish Orphan Biovitrum AB should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Swedish Orphan Biovitrum AB for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Swedish Orphan Biovitrum AB
-100.0%
76.75
30.18%
OMX Stockholm 30
17.06%
0.95
17.88%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
12.34%
EBIT Growth (5y)
8.66%
EBIT to Interest (avg)
6.87
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.45
Tax Ratio
12.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.02%
ROE (avg)
10.77%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.75
EV to EBIT
18.51
EV to EBITDA
11.77
EV to Capital Employed
2.36
EV to Sales
4.42
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
12.73%
ROE (Latest)
11.90%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company
PRE-TAX PROFIT(Q)

At SEK 1,031 MM has Grown at 238.03%

NET PROFIT(Q)

At SEK 825.24 MM has Grown at 232.17%

DEBT-EQUITY RATIO (HY)

Lowest at 30.09 %

RAW MATERIAL COST(Y)

Fallen by -5.21% (YoY

CASH AND EQV(HY)

Highest at SEK 2,055 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.34%

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS

Here's what is working for Swedish Orphan Biovitrum AB

Pre-Tax Profit
At SEK 1,031 MM has Grown at 238.03%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (SEK MM)

Net Profit
At SEK 825.24 MM has Grown at 232.17%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (SEK MM)

Debt-Equity Ratio
Lowest at 30.09 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Cash and Eqv
Highest at SEK 2,055 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 2.34%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -5.21% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales